@ Stay054 "Palliative direct beam radiotherapy is not a payload...

@ Stay054 "Palliative direct beam radiotherapy is not a payload that could reasonably have been expected to have given Veyonda much assistance to make a difference"

Bit late for toning it down now......

Posted on March 29th, 2018
Since Noxopharm’s ASX release last Wednesday about seeing abscopal responses in two patients receiving NOX66, some shareholders have asked me what it means to the future treatment of cancer. The short answer is, potentially a great deal. By any definition, it is ‘disruptive technology’ that has the potential to change the face of cancer therapy.

"One interesting outcome of DARRT-1, or any of the immuno-oncology/radiotherapy studies, if they are successful and if there is a strong and durable complete abscopal response in a high proportion of patients, is what effect it will have on the future of chemotherapy drugs currently under development.

"A clinical-stage oncology drug company developing a disruptive technology for the treatment of solid cancers by radiotherapy and chemotherapy" (Open Briefing June 2018)